Geno Germano Purchases 20,000 Shares of Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Geno Germano bought 20,000 shares of the stock in a transaction on Monday, March 9th. The shares were bought at an average cost of $1.30 per share, for a total transaction of $26,000.00. Following the purchase, the director owned 40,000 shares in the company, valued at $52,000. This trade represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Entera Bio Stock Performance

Shares of ENTX stock traded up $0.04 during midday trading on Friday, reaching $1.36. 3,466 shares of the company were exchanged, compared to its average volume of 209,020. The company’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $1.95. The company has a market cap of $62.37 million, a P/E ratio of -5.44 and a beta of 1.83. Entera Bio Ltd. has a 12 month low of $1.00 and a 12 month high of $3.22.

Institutional Trading of Entera Bio

A number of large investors have recently added to or reduced their stakes in the business. Superstring Capital Management LP acquired a new position in Entera Bio in the fourth quarter worth approximately $33,000. Citadel Advisors LLC lifted its position in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after acquiring an additional 25,000 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after acquiring an additional 19,601 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, December 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research note on Monday, February 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.